Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)

PHARMACOLOGY Correction for "Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer," by Sandra Blasco-Benito, Estefania Moreno, Marta Seijo-Vila, Isabel Tundidor, Clara Andradas, Maria M. Caffarel, Miriam Caro-Villalobos, Leyre Uriguen, Rebeca Diez-Alarcia, Gema Moreno-Bueno, Lucia Hernandez, Luis Manso, Patricia Homar-Ruano, Peter J. McCormick, Lucka Bibic, Cristina Bernado-Morales, Joaquin Arribas, Meritxell Canals, Vicent Casado, Enric I. Canela, Manuel Guzman, Eduardo Perez-Gomez, and Cristina Sanchez, which was first published February 7, 2019; 10.1073/pnas.1815034116 (Proc Natl Acad Sci USA 116:3863-3872). The authors note that, due to a printer's error, the affiliation for Lucka Bibic appeared incorrectly. It should instead appear as School of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, United Kingdom. The corrected author and affiliation lines appear below. The online version has been corrected.